Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

The Patent Act provides that “the reissued patent, to the extent its claims are substantially identical with the original patent, shall constitute a continuation thereof and have effect continuously from the date of the original patent.” 35 U.S.C. § 252.

"its claims are substantially identical with the original patent"

Who makes this decision in a case like ours? The presiding Judge or the PTO?

Share
New Message
Please login to post a reply